Mankind Pharma Ltd reported a consolidated net profit of ₹511.5 crore for the September quarter, down 21.7% year-on-year from ₹653.4 crore, even as revenue rose 20.8% to ₹3,697 crore from ₹3,061 crore a year ago.

EBITDA increased 8.8% to ₹921.8 crore, while margins contracted to 24.9% from 27.7% a year earlier.

Rajeev Juneja, Vice Chairman and Managing Director, said the company’s strong topline growth was supported by continued outperformance in its chronic portfolio and the consolidation of Biopharma Solutions Ventures (BSV), though the quarter was partially impacted by GST-related supply disruptions.

“While chronic continued to outperform led by 1.3x and 1.2x growth in Cardiac and Anti-diabetes respectively, OTC was impacted due to heavy rains along with GST 2.0, and we expect growt

See Full Page